Global Overactive Bladder Therapeutics Market Is Estimated To Witness Significant Growth Due To Increasing Geriatric Population And Growing Frequency Disorders
Overview:
Symptomatic overactive bladder, also known as urge urinary incontinence, is a common condition affecting 12-17% of the population. It can have significant consequences for quality of life, including work, social activities, exercise and sleep. First-line treatment includes lifestyle interventions, pelvic floor exercises, bladder training and antimuscarinic agents. When these are not effective, urology referral is necessary. Second-line therapy involves invasive treatments such as botulinum toxin, neuromodulation or surgical procedures such as augmentation cystoplasty or urinary diversion.
These therapies can help alleviate symptoms and improve the quality of life. Third-line therapies are based on more recent data and include intradetrusor injection of onabotulinumtoxinA, peripheral tibial nerve stimulation and sacral neuromodulation. Fourth-line therapy is also considered for patients with refractory OAB and includes the use of augmentation cystoplasty or urinary diversion. Medication side effects can be more of an issue for older patients or those with other medical problems, such as high blood pressure or memory loss.
Market Dynamics:
Increasing research and developmental activities are estimated to augment growth of the global Overactive Bladder Therapeutics Market over the forecast period. For instance, Urovant Sciences, presented the data of their Phase 3 EMPOWUR Extension Study of GEMTESA in May 2022. This study will confirm the durability and potential utility in patient population and examine their long-term effects. Moreover, increasing product recalls are anticipated to restrain growth of the global overactive bladder therapeutics for market over the forecast period.
Impact of COVID-19:
The pandemic was first recognized in 2019 in China and in 2020 it was declared as a public health emergency. The pandemic affected the demand and production of several markets. Many countries like Spain, Italy, France, India, China and many more implemented strict lockdowns for preventing further spread off the virus. This led to shutting down of manufacturing units, and factories.
Supply chains were also disrupted owing to the pandemic. Thus, there was a shortage of raw materials in various industries. This hampered the demand for overactive bladder therapeutics. Thus, the global Overactive Bladder Therapeutics Market was affected in a negative manner due to the pandemic.
Key Takeaways:
The global Overactive Bladder Therapeutics Market is expected to witness high growth, exhibiting CAGR of 3.6 % over the forecast period, due to rising product launches.
For instance, Fesoterodine fumarate extended-release tablets, were introduced by Dr. Reddy’s Laboratories in July 2022. These tablets are a therapeutic generic equivalent to Toviaz by Pfizer in the US for treating overactive bladder.
North America is anticipated to witness significant growth in the global overactive bladder therapeutics for market over the forecast period, owing to well-developed healthcare infrastructure.
Major players operating in the global Overactive Bladder Therapeutics Market are Hugel, AbbVie, Bayer AG, Astellas Pharma, Laborie, Intas Pharmaceuticals, Endo International PLC, Glenmark, Hisamitsu Pharmaceutical, Sun Pharmaceutical, Johnson & Johnson Services, Uro Medical, Medtronic, Lupin, Pfizer, Urovant Sciences, Sanofi, Macleods Pharmaceuticals, Viatris, Hisamitsu, and Teva Pharmaceutical.
Comments
Post a Comment